This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ATNX Athenex (ATNX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Athenex Stock (NASDAQ:ATNX) 30 days 90 days 365 days Advanced Chart Get Athenex alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.20▼$1.5252-Week Range N/AVolume1.88 million shsAverage Volume194,316 shsMarket Capitalization$1.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. Read More Receive ATNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNX Stock News HeadlinesBiopharmaceutical company expands in time to take on Athenex businessDecember 26, 2023 | bizjournals.comOnly 2 local CEOs score highly with both employees and investorsNovember 22, 2023 | bizjournals.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 10 at 2:00 AM | Brownstone Research (Ad)Athenex assets sold in bankruptcy auction; top executives dismissedJuly 31, 2023 | bizjournals.comAthenex (NASDAQ: ATNX)June 11, 2023 | fool.comBuffalo's drug development scene expected to continue in Athenex's wakeJune 1, 2023 | bizjournals.comAthenex to lay off 123 WNY employees, close both Buffalo-area plants by mid-AugustMay 17, 2023 | bizjournals.comAthenex, Inc. (ATNX) stock price, news, quote & history – Yahoo FinanceMay 16, 2023 | uk.finance.yahoo.comSee More Headlines ATNX Stock Analysis - Frequently Asked Questions How were Athenex's earnings last quarter? Athenex, Inc. (NASDAQ:ATNX) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.08. The business had revenue of $32.30 million for the quarter, compared to the consensus estimate of $19.40 million. Athenex had a negative net margin of 86.31% and a negative trailing twelve-month return on equity of 727.79%. When did Athenex IPO? Athenex (ATNX) raised $72 million in an initial public offering (IPO) on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager. What other stocks do shareholders of Athenex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Athenex investors own include TherapeuticsMD (TXMD), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO), NVIDIA (NVDA), Tesla (TSLA) and Ford Motor (F). Company Calendar Last Earnings11/04/2021Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATNX CIK1300699 Webwww.athenex.com Phone(716) 427-2950FaxN/AEmployees652Year Founded2003Profitability EPS (Trailing Twelve Months)($15.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.43 million Net Margins-86.31% Pretax Margin-95.92% Return on Equity-727.79% Return on Assets-44.44% Debt Debt-to-Equity Ratio3.08 Current Ratio1.09 Quick Ratio0.72 Sales & Book Value Annual Sales$102.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($3.07) per share Price / BookN/AMiscellaneous Outstanding Shares8,660,000Free Float7,866,000Market Cap$1.76 million OptionableOptionable Beta1.36 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ATNX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our Partners#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athenex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.